Survival Analysis of Patients Undergoing Intraoperative Contrast enhanced Ultrasound in the Surgical Treatment of Malignant Glioma

Scientists show that #ICEUS improves #ResidualTumor detection during malignant #glioma surgery and is linked to better overall and #ProgressionFreeSurvival, highlighting ICEUS as a #prognosticfactor and tool to enhance surgical outcomes.
Read: doi.org/10.1007/s115...

#Culmerciclib combined with #fulvestrant significantly improved #ProgressionFreeSurvival and response rate in pretreated HR‑positive, #HER2‑negative advanced #BreastCancer, supporting combined CDK2/4/6 blockade as a promising therapeutic strategy.

#STTT: doi.org/10.1038/s413...

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type...

This phase 3 trial shows that cetuximab β plus #FOLFIRI significantly improves #ProgressionFreeSurvival, overall survival, and response rates compared to FOLFIRI alone in RAS/BRAF wild-type #MetastaticColorectalCancer with manageable toxicity.

#STTT:

First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or...

This phase Ib/II trial reports that the NASCA regimen achieved higher ORR and longer #ProgressionFreeSurvival than nab‑paclitaxel/gemcitabine, with manageable safety, highlighting its promise for treating advanced #PancreaticDuctalAdenocarcinoma.

#STTT: doi.org/10.1038/s413...

This phase III trial demonstrates that #ARX788 significantly improves #ProgressionFreeSurvival over lapatinib plus capecitabine in #HER2-positive advanced #BreastCancer, showing strong efficacy and manageable ocular and #PulmonaryToxicity.

#OpenAccess #STTT: doi.org/10.1038/s413...

The NASCA regimen—surufatinib, #camrelizumab, nab-paclitaxel, and S-1—achieved superior response and #progressionfreesurvival in #metastatic #PancreaticDuctalAdenocarcinoma, with immune and #biomarker profiling predicting improved outcomes. #medsky

#STTT: doi.org/10.1038/s413...

Scotland approves new treatment option for multiple myeloma patients - PharmaTimes Blenrep combination offers improved survival for those ineligible for lenalidomide

#Haematology #Oncology #Scotland #NHSScotland #multiplemyeloma #GSK #Blenrep #belantamabmafodotin #Blenrepcombination #lenalidomide #ScottishMedicinesConsortium #SMC #bortezomibanddexamethasone #BVd #SMCrecommendation #phase3data #DREAMM7study #progressionfreesurvival
zurl.co/ydmDa

This retrospective study reveals that #ThoracicRadiotherapy (RT) can significantly delay the development of resistance to 3GEGFR-TKIs and prolong #progressionfreesurvival (PFS) in advanced #NonSmallCellLungCancer (NSCLC) patients.

Read more: link.springer.com/article/10.1...

Investigational drug more than doubles survival time for glioblastoma patients – BioNews Central A unique investigational drug formulation more than doubled the median survival and progression-free survival times of glioblastoma patients without causing dose-limiting toxic effects. ...

A unique #InvestigationalDrug formulation more than doubled the median #survival and #ProgressionFreeSurvival times of #glioblastoma patients without causing dose-limiting toxic effects.
#BrainCancer